September 3, 2020 -- Clinical-stage biotechnology company Magenta Therapeutics has joined a broad-based research effort to explore gene- and cell-based approaches to cure HIV.
The U.S. National Institutes of Health (NIH) awarded the group a five-year, $14.9 million U19 grant to advance the research into hematopoietic stem and progenitor cell (HSPC) engineering and transplantation with the goal of complete HIV-1 infection remission.
As part of the program, Magenta will optimize cell dose in animal models and determine whether HSPC transplant results in disease control. The project includes researchers studying gene editing, HIV, and stem cell transplantation at a number of premier institutions, including the University of Southern California, the University of Washington, and Harvard University.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
